Nicoboxil

Summary

Nicoboxil (CHEMBL2105161) is a phase-3 clinical-stage small molecule; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 223.27 Da · C12H17NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105161
Name	Nicoboxil
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	14866
Molecular formula	C12H17NO3
Molecular weight	223.27
InChIKey	IZJRISIINLJVBU-UHFFFAOYSA-N

SMILES: CCCCOCCOC(=O)C1=CN=CC=C1

IUPAC name: 2-butoxyethyl pyridine-3-carboxylate

Also known as: Beta-butoxyethyl nicotinate, Butoxyethyl nicotinate, Nicoboxil, Nicoboxilo, SID170465989, NICOBOXIL

Patent coverage: 411 distinct patent families (1,006 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 995 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01708915	PHASE3	COMPLETED	Nonivamide/Nicoboxil Ointment in Acute Low Back Pain

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).